Search results for "malignancies"

showing 10 items of 34 documents

Incidence of hematologic malignancies in Europe by morphologic subtype: Results of the HAEMACARE project

2010

AbstractChanging definitions and classifications of hematologic malignancies (HMs) complicate incidence comparisons. HAEMACARE classified HMs into groupings consistent with the latest World Health Organization classification and useful for epidemiologic and public health purposes. We present crude, age-specific and age-standardized incidence rates for European HMs according to these groupings, estimated from 66 371 lymphoid malignancies (LMs) and 21 796 myeloid malignancies (MMs) registered in 2000-2002 by 44 European cancer registries, grouped into 5 regions. Age-standardized incidence rates were 24.5 (per 100 000) for LMs and 7.55 for MMs. The commonest LMs were plasma cell neoplasms (4.6…

Malemedicine.medical_specialtyPathologyChildhood leukemiaHematologic malignant; Europe; morphologic subtype; international comparison; population-based cancer registry.ImmunologyPopulationUNITED-STATESALCOHOLBiochemistryNOMyelodysplastic–myeloproliferative diseasesInternal medicineEpidemiologymorphologymedicineLYMPHOMAHumansEPIDEMIOLOGYRegistriesEXPOSUREeducationRISKeducation.field_of_studyTOBACCOhaematologic malignanciesbusiness.industryIncidence (epidemiology)IncidenceleukemiaMyeloid leukemiaCell BiologyHematologyHematologic malignancies; morphology; Europe.Plasma cell neoplasmmedicine.diseaseMyelodysplastic-Myeloproliferative DiseasesLymphomaEuropeCANCER INCIDENCEHematologic Neoplasmscancer incidence tobacco alcohol epidemiology leukemia risk exposureCHILDHOOD LEUKEMIAHematologic malignanciesFemalebusiness
researchProduct

A Brief Synopsis on Scalp Melanoma

2020

Melanoma constitutes one of the most sinister and troublesome malignancies encountered by humanity. Generally, the diagnosis of advanced melanoma connotes a grave prognosis, prompting a sense of looming threat of death, however, the early-stage detected disease responds well to robust treatment resulting in reasonable survivorship. Scalp melanomas are even more troublesome, because they typically exhibit more aggressive biologic behavior and are often diagnosed at a late stage. This review tries to comprehensively highlight the various diagnostic, therapeutic, and outcome aspects of scalp melanomas. The literature research includes peer-reviewed articles (clinical trials or scientific revie…

Melanomasmedicine.medical_specialtySkin NeoplasmsMEDLINEDermatologyEnglish languageDiseaseBreslow thickness; head and neck melanomas; melanomas; scalp melanomas; skin malignancies; Humans; Prognosis; Scalp; Head and Neck Neoplasms; Melanoma; Skin NeoplasmsBreslow thickne030207 dermatology & venereal diseases03 medical and health sciences0302 clinical medicinemedicineHumansMelanomaScalp melanomaAdvanced melanomaScalpHead and neck melanomabusiness.industryMelanomaLate stageHead and neck melanomasGeneral MedicinePrognosismedicine.diseaseDermatologyBreslow thickness; Head and neck melanomas; Melanomas; Scalp melanomas; Skin malignanciesClinical trialmedicine.anatomical_structureScalp melanomasHead and Neck NeoplasmsSkin malignancies030220 oncology & carcinogenesisScalpbusinessBreslow thickness
researchProduct

Risk factors of de novo malignancies after liver transplantation: a French national study on 11004 adult patients.

2021

International audience; Background: After liver transplantation (LT),de novo malignancies are one of the leading causes of late mortality. The aim of the present retrospective study was to identify the risk factors of de novo malignancies in a large cohort of LT recipients in France, using Fine and Gray competing risks regression analysis.Methods: The study population consisted in 11004 adults transplanted between 2000 and 2013, who had no history of pre-transplant malignancy, except primary liver tumor. A Cox model adapted to the identification of prognostic factors (competitive risks) was used.Results: From the entire cohort, one (or more)de novo malignancy was reported in 1480 L T recipi…

OncologyAdultMalemedicine.medical_specialtyMESH: Liver TransplantationLiver tumormedicine.medical_treatmentLiver transplantationMalignancyPrimary sclerosing cholangitis03 medical and health sciencesLiver disease0302 clinical medicineMESH: Liver NeoplasmsMESH: Risk FactorsRisk FactorsInternal medicinemedicineHumansMESH: IncidenceLung cancerRetrospective StudiesMESH: HumansHepatologybusiness.industryIncidenceLiver NeoplasmsGastroenterologyRetrospective cohort studyMESH: AdultMESH: Retrospective Studies[SDV.MHEP.HEG]Life Sciences [q-bio]/Human health and pathology/Hépatology and GastroenterologyCompeting riskmedicine.disease[SDV.MHEP.HEG] Life Sciences [q-bio]/Human health and pathology/Hépatology and GastroenterologyMESH: MaleLiver Transplantation030220 oncology & carcinogenesisPopulation study030211 gastroenterology & hepatologybusinessLiver transplantationde novomalignanciesClinics and research in hepatology and gastroenterology
researchProduct

Incidence, survival and prevalence of myeloid malignancies in Europe.

2012

Abstract Background The Surveillance of Rare Cancers in Europe (RARECARE) project aims at increasing knowledge of rare cancers in Europe. This manuscript describes the epidemiology of myeloid malignancies (MMs), taking into account the morphological characterisation of these tumours. Methods We used data gathered by RARECARE on cancer patients diagnosed from 1995 to 2002 and archived in 64 European population-based cancer registries, followed up to 31st December 2003 or later. Results The overall annual crude incidence of MMs was 8.6 per 100,000. Acute myeloid leukaemia (AML) and myeloproliferative neoplasms (MPN) were most common, with incidence rates of 3.7 and 3.1 per 100,000 year respec…

OncologyMyeloidMaleCancer ResearchMyeloidSurvivalChronic myelomonocytic leukaemiaCancer registry Incidence Prevalence Survival Myeloid malignancies Acute myeloid leukaemia Myelodysplastic syndrome Chronic myeloid leukaemia Chronic myelomonocytic leukaemiaImmunophenotypingEpidemiologyPrevalenceChildLeukemiaIncidence (epidemiology)IncidenceMyeloid malignanciesCancer registryMiddle AgedEuropeLeukemia Myeloid AcuteLeukemiamedicine.anatomical_structureOncologyChild PreschoolMyelodysplastic-Myeloproliferative Diseases/epidemiology/mortalityMyelodysplastic Syndromes/epidemiology/mortalityFemaleAdultmedicine.medical_specialtyAdolescentAcute myeloid leukaemiaNOEurope/epidemiologyInternal medicinemedicinecancer Incidence; survival and prevalence; myeloid malignanciesHumansPreschoolChronic myeloid leukaemiaddc:613AgedMyeloproliferative Disorders/epidemiology/mortalityMyeloproliferative Disordersbusiness.industryMyelodysplastic syndromesInfant NewbornCancerInfantcancer Incidencemedicine.diseaseNewbornMyelodysplastic-Myeloproliferative DiseasesCancer registrysurvival and prevalenceMyelodysplastic SyndromesImmunologyAcute/epidemiology/mortalitybusinessMyelodysplastic syndrome
researchProduct

Human bone marrow mesenchymal stem cells display anti-cancer activity in SCID mice bearing disseminated non-Hodgkin's lymphoma xenografts.

2010

Background Although multimodality treatment can induce high rate of remission in many subtypes of non-Hodgkin's lymphoma (NHL), significant proportions of patients relapse with incurable disease. The effect of human bone marrow (BM) mesenchymal stem cells (MSC) on tumor cell growth is controversial, and no specific information is available on the effect of BM-MSC on NHL. Methodology/Principal Findings The effect of BM-MSC was analyzed in two in vivo models of disseminated non-Hodgkin's lymphomas with an indolent (EBV− Burkitt-type BJAB, median survival = 46 days) and an aggressive (EBV+ B lymphoblastoid SKW6.4, median survival = 27 days) behavior in nude-SCID mice. Intra-peritoneal (i.p.) i…

Pathologymedicine.medical_specialtyStromal cellTransplantation HeterologousMice Nudelcsh:Medicinemesenchimal stem cellsMice SCIDMiceimmune system diseaseshemic and lymphatic diseasesmesenchymal stem cells non-Hodgkin's lymphoma.AnimalsHumansMedicinehuman lymphoma xenograft; mesenchimal stem cellsOncology/Hematological Malignancieslcsh:ScienceSCID MiceMultidisciplinaryHematology/Bone Marrow and Stem Cell Transplantationbusiness.industryLymphoma Non-HodgkinLymphoblastlcsh:RMesenchymal stem cellNon-Hodgkin's LymphomaMesenchymal Stem CellsHematopoietic Stem Cellsmedicine.diseaseCoculture TechniquesLymphomaNon-Hodgkin's lymphomaEndothelial stem cellTransplantationApoptosislcsh:QHematology/Lymphomas and Chronic Lymphoblastic LeukemiabusinessMesenchymal Stem Cells; SCID Mice; Non-Hodgkin's LymphomaResearch Articlehuman lymphoma xenograft
researchProduct

Out-of-the-box pelvic surgery including iliopsoas resection for recurrent gynecological malignancies: Does that make sense? A single-institution case…

2017

Abstract Objective To report morbidity and oncological outcomes in a consecutive series of lateral isolated recurrent gynecological cancer involving the pelvic side wall (PSW) including the iliopsoas muscle. Material and methods We retrospectively evaluated a consecutive series between 6/2013 and 12/2015 of lateral isolated recurrent gynecological malignancies treated with a lateral endopelvic resection (LEPR). LEPR was defined as an en-bloc lateral resection of a pelvic tumor with sidewall muscle, and/or bone, and/or major nerve, and/or major vascular structure. Post-surgical complications, quality of life (QoL) and survivals were computed. Results Seventy-four women with pelvic isolated r…

Pelvic NeoplasmPsoas MusclePostoperative Complications0302 clinical medicineQuality of lifeRetrospective StudieUterine NeoplasmPelvic Neoplasms030212 general & internal medicineIliopsoas resection; Lateral endopelvic resection; Pelvic side wall disease; Recurrent gynecological malignanciesPelvic NeoplasmsPsoas MusclesOvarian NeoplasmsPelvic side wall diseaseGraft Occlusion VascularPeripheral Nervous System DiseasesIliopsoas resectionGeneral MedicineMiddle AgedThrombosisCompartment SyndromeTreatment OutcomeOncology030220 oncology & carcinogenesisUterine NeoplasmsThrombosiFemaleIliopsoasHumanAdultmedicine.medical_specialtyIliopsoas MuscleIliopsoas resection; Lateral endopelvic resection; Pelvic side wall disease; Recurrent gynecological malignancies; Adult; Aged; Compartment Syndromes; Disease-Free Survival; Female; Graft Occlusion Vascular; Humans; Middle Aged; Muscle Skeletal; Neoplasm Recurrence Local; Ovarian Neoplasms; Pelvic Neoplasms; Peripheral Nervous System Diseases; Postoperative Complications; Psoas Muscles; Quality of Life; Retrospective Studies; Thrombosis; Treatment Outcome; Uterine Neoplasms; Surgery; OncologyCompartment SyndromesDisease-Free Survival03 medical and health sciencesmedicineHumansMuscle SkeletalRetrospective StudiesAgedbusiness.industryOvarian NeoplasmThrombosisRetrospective cohort studyPerioperativeRecurrent gynecological malignanciemedicine.diseaseSurgerySettore MED/40 - GINECOLOGIA E OSTETRICIAQuality of LifeLateral endopelvic resectionPelvic tumorSurgeryPostoperative ComplicationRecurrent gynecological malignanciesNeoplasm Recurrence LocalPeripheral Nervous System DiseasebusinessEuropean Journal of Surgical Oncology (EJSO)
researchProduct

Identification of pyrrolo[3',4':3,4]cyclohepta[1,2-d][1,2]oxazoles as promising new candidates for the treatment of lymphomas

2023

Unsatisfactory outcomes for relapsed/refractory lymphoma patients prompt continuing efforts to develop new therapeutic strategies. Our previous studies on pyrrole-based anti-lymphoma agents led us to synthesize a new series of twenty-six pyrrolo[3′,4':3,4]cyclohepta[1,2-d] [1,2]oxazole derivatives and study their antiproliferative effects against a panel of four non-Hodgkin lymphoma cell lines. Several candidates showed significant anti-proliferative effects, with IC50's reaching the sub-micromolar range in at least one cell line, with compound 3z demonstrating sub-micromolar growth inhibitory effects towards the entire panel. The VL51 cell line was the most sensitive, with an IC50 value of…

Pharmacology2-d][1Antitumor agentsLymphoma4’:3Organic ChemistryGeneral MedicineIsoxazolespyrrolo[3′2]oxazolesHematological malignanciesAntitumor agents; Hematological malignancies; Isoxazoles; Lymphoma; pyrrolo[3′4’:34]cyclohepta[12-d][12]oxazolespyrrolo[3′4’:34]cyclohepta[12-d][12]oxazoles4]cyclohepta[1Drug Discovery
researchProduct

Heat shock proteins: essential proteins for apoptosis regulation

2008

Abstract Many different external and intrinsic apoptotic stimuli induce the accumulation in the cells of a set of proteins known as stress or heat shock proteins (HSPs). HSPs are conserved proteins present in both prokaryotes and eukaryotes. These proteins play an essential role as molecular chaperones by assisting the correct folding of nascent and stress-accumulated misfolded proteins, and by preventing their aggregation. HSPs have a protective function, that is they allow the cells to survive to otherwise lethal conditions. Various mechanisms have been proposed to account for the cytoprotective functions of HSPs. Several of these proteins have demonstrated to directly interact with compo…

Programmed cell deathCell signalingReviewsMitochondrionBiologyModels BiologicallysosomesLysosomeHeat shock proteindeath receptorsmedicineAnimalsHumansemerging chemotherapeutic treatmentsHeat-Shock ProteinsCell Deathhaematopoietic malignanciesapoptosiscell signallingCell BiologyMitochondriaNeoplasm ProteinsCell biologymedicine.anatomical_structurecaspasesHematologic Neoplasmsheat shock proteinsMolecular MedicineProtein foldingHSP60Signal transductionMolecular ChaperonesSignal TransductionJournal of Cellular and Molecular Medicine
researchProduct

Evaluation of the impact of therapeutic management on the survival and quality of life of patients with follicular lymphoma or diffuse large B cell l…

2014

In France, hematologic malignancies, which are the sixthmost common cancers, are amajor public healthproblem. This work aimed to study the impact of the therapeutic management on survival and healt-relatedquality of life (HRQoL) in patients with these hematologic malignancies. The first objective of this work is topresent an overview of the epidemiology of lymphoid malignancies with a study of changes in the incidenceand net survival in the Côte d’Or department between 1980 and 2009. The incidence, which has increased since1980, seems to have stabilized since the 2000s for some entities, including follicular lymphoma (FL) and diffuselarge B-cell lymphoma (DLBCL). Overall, we observed an imp…

Propensity scoreSurvie netteQualité de vie relative à la santéHealth-related quality of lifeIncidenceHémopathie lymphoïdeDiffuse large B-cell lymphomaLymphome folliculaireLymphome B diffus à grandes cellulesFollicular lymphomaNet survivalSurvie globale[SDV.SPEE] Life Sciences [q-bio]/Santé publique et épidémiologieScore de propensionHematologic malignanciesOverall survivalRituximab
researchProduct

miR-29s: A family of epi-miRNAs with therapeutic implications in hematologic malignancies

2015

A wealth of studies has highlighted the biological complexity of hematologic malignancies and the role of dysregulated signal transduction pathways. Along with the crucial role of genetic abnormalities, epigenetic aberrations are nowadays emerging as relevant players in cancer development, and significant research efforts are currently focusing on mechanisms by which histone post-translational modifications, DNA methylation and noncoding RNAs contribute to the pathobiology of cancer. As a consequence, these studies have provided the rationale for the development of epigenetic drugs, such as histone deacetylase inhibitors and demethylating compounds, some of which are currently in advanced p…

ReviewTumor initiationhematologic malignancieEpigenesis GeneticmicroRNAmedicineAnimalsHumansMolecular Targeted TherapyEpigeneticsmiR-29cbiologymiR-29abusiness.industrymiR-29bCancerDNA Methylationhematologic malignanciesmedicine.diseasemultiple myelomaMicroRNAsHistoneOncologyHematologic NeoplasmsDNA methylationImmunologyCancer researchbiology.proteinHistone deacetylaseSignal transductionbusiness
researchProduct